Clinical Trial Update: Japanese BAY88-8223 Monotherapy Phase II Study [Phase 2]

View source ↗

Summary

A Phase II monotherapy study of BAY-88-8223 in Japanese patients with prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• BAY-88-8223

Snippet

Sponsor: Bayer | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED